Economics of Minimalist Transcatheter Aortic Valve Replacement: Results From the 3M-TAVR Economic Study
Neel M. Butala,David A. Wood,Haiyan Li,Khaja Chinnakondepalli,Sandra B. Lauck,Janarthanan Sathananthan,John A. Cairns,Elizabeth A. Magnuson,Madeleine Barker,John G. Webb,Robert Welsh,Anson Cheung,Jian Ye,James L. Velianou,Harindra C. Wijeysundera,Anita Asgar,Susheel Kodali,Vinod H. Thourani,David J. Cohen,on behalf of the 3M-TAVR Investigators
DOI: https://doi.org/10.1161/CIRCINTERVENTIONS.122.012168
2022-10-19
Abstract:The 3M-TAVR trial (3M-Transcatheter Aortic Valve Replacement) demonstrated the feasibility and safety of next-day hospital discharge after transfemoral TAVR with implementation of a minimalist pathway. However, the economic impact of this approach is unknown. Therefore, we evaluated costs for patients undergoing minimalist TAVR compared with conventional TAVR. We used propensity matching to compare resource utilization and costs (from a US health care system perspective) for patients in the 3M-TAVR trial with those for transfemoral TAVR patients enrolled in the contemporaneous S3i trial (PARTNER SAPIEN-3 Intermediate Risk). Procedural costs were estimated using measured resource utilization for both groups. For the S3i group, all other costs through 30-day follow-up were assessed by linkage with Medicare claims; for 3M, these costs were assessed using regression models derived from S3i cost and resource utilization data. After 1:1 propensity matching, 351 pairs were included in our study (mean age 82, mean Society of Thoracic Surgery risk score 5.3%). There were no differences in death, stroke, or rehospitalization between the 3M-TAVR and S3i groups through 30-day follow-up. Index hospitalization costs were 11 305/patient lower in the 3M-TAVR cohort compared with the S3i cohort ( 60 729, 95% CI for difference 13 138; P <0.001). Compared with conventional transfemoral TAVR, use of a minimalist pathway in intermediate-risk patients was associated with similar clinical outcomes and substantial in-hospital cost savings, which were sustained through 30 days. URL: https://www.clinicaltrials.gov; Unique identifier: NCT02287662. Download figure Download PowerPoint
cardiac & cardiovascular systems